All In Biotech

Drug Trial Radar · NCT00083993

Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Oral CCI-779 Administered in Combination With Letrozole vs. Letrozole Alone as First Line Hormonal Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Last checked: Nov 20, 2026Latest source record: Nov 8, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 1,236 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,236

Actual

Start

May 2004

Primary completion

Oct 2006

Study completion Oct 2006

Sponsor

Sponsor type
Industry
First posted
Jun 8, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this clinical research study, postmenopausal subjects with metastatic breast cancer will be given either the combination of temsirolimus (CCI-779) and letrozole or a placebo and letrozole in first-line hormonal treatment. The primary endpoint of this study is to determine overall progression free survival. Individual subjects will participate in the active treatment phase of the study until disease progression or withdrawal of consent, provided that test article is being tolerated. All subjects will be asked to participate in the long-term follow-up phase of the study, which includes follow-up every 3 months until disease progression (for subjects who withdraw for reasons other than documented progressive disease) or until any new cancer treatment is received, and for survival. The estimated duration of study participation is 34 months.

Conditions

  • Breast Neoplasms
  • Neoplasm Metastasis

Interventions

  • Temsirolimus (CCI-779) for 34 monthsDrug

  • Letrozole for 34 monthsDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine overall progression free survival.

Locations

129 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Hoover, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Tucson, Arizona

  • Site not named

    Jonesboro, Arkansas

  • Site not named

    Burbank, California

  • Site not named

    Campbell, California

  • Site not named

    Fountain Valley, California

  • Site not named

    Gilroy, California

  • Site not named

    Glendora, California

  • Site not named

    Modesto, California

  • Site not named

    Montebello, California

  • Site not named

    Pomona, California

  • Site not named

    Poway, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    Santa Rosa, California

  • Site not named

    Soquel, California

  • Site not named

    Vista, California

  • Site not named

    Lakewood, Colorado

  • Site not named

    Norwalk, Connecticut

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Boca Raton, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Hollywood, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Lake Worth, Florida

  • Site not named

    Miami Shores, Florida

  • Site not named

    New Port Richey, Florida

  • Site not named

    Plantation, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    Zephyrhills, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Columbus, Georgia

  • Site not named

    Roswell, Georgia

  • Site not named

    Thomasville, Georgia

  • Site not named

    Coeur d'Alene, Idaho

  • Site not named

    Centralia, Illinois

  • Site not named

    Skokie, Illinois

  • Site not named

    Skokie, Illinois

Showing 40 of 129 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.